Trial shows significant improvements in early Parkinson’s disease
BioVie has announced results from its Phase II SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease (PD).
The SUNRISE-PD trial was a Phase II, multicentre, randomised, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept in patients with early-stage PD that had not previously been treated with carbidopa/levodopa.
Under the statistical analysis plan submitted to the US Food and Drug Administration (FDA), the study’s primary pharmacodynamic assessment focused on changes in a predefined panel of blood-based inflammatory markers of disease. The study also evaluated motor and non-motor endpoints, clinician-rated outcomes, quality-of-life, and safety and tolerability measures.
The trial successfully met prespecified endpoints and achieved its objectives, with topline results showing that bezisterim improved blood based inflammatory markers of disease, along with a broad range of biological markers associated with overall cellular health and nerve cell damage.
Participants treated with bezisterim experienced greater improvements than those receiving placebo across a series of clinical outcome measures of daily living, motor symptoms, and non-motor symptoms.
Cuong Do, President and CEO of BioVie, said: “These exploratory results suggest that bezisterim may have the potential to become the first drug candidate to improve clinical outcomes in Parkinson’s disease beyond motor symptoms. The findings also indicate a potentially differentiated profile, with effects on underlying proteomic and biomarker endpoints, potential neurodegenerative benefits, and improvements across both motor as well as non-motor clinical outcomes.”
Greater improvement with higher inflammation
The majority of patients treated with bezisterim showed improvement on EPNIC-15,2 a composite endpoint encompassing 15 clinically relevant motor and non-motor measures of PD. In contrast, patients receiving placebo showed a change in the opposite direction.
The greatest improvement was seen in those with higher levels of inflammation at baseline. Baseline platelet concentration, a biomarker associated with inflammatory status, identified subgroups in which treatment effects were more pronounced, providing further support for a potential role of inflammation in Parkinson’s disease.
Among patients with baseline platelet counts >230 x103/µL, who represent approximately one-half of the trial population, bezisterim treatment was associated with statistically significant advantages over placebo across all clinical measures evaluated, including EPNIC-15 and MDS-UPDRS Parts I, II, and III, and MDS-UPDRS Total.
“Improvement across both motor and non-motor domains of the MDS-UPDRS is encouraging because these measures represent clinically meaningful outcomes recognised by physicians, patients, and the FDA,” said Dr Mark Stacy, William E Murray Professor of Neurology at the Medical University of South Carolina. “The finding that treatment effects were greater in patients with higher platelet levels supports the rationale that reduction in neuronal inflammation remains an unmet need in neurodegenerative disease. It may also provide guidance for evaluating a more targeted patient population in future studies.”
